ReviewFrontiers in immunology2025
Cross-talk between aging resilience pathways and autoimmunity onset.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Biomarker Out of Context: Understanding High p-tau217 in the Developing Brain.Molecular neurobiology · 2026Review
- Genetic Determinants of T-Cell Homeostasis in Critical Illness: An Exploratory Analysis of Immune Gene Variants and TREC Dynamics.Journal of personalized medicine · 2026Article
- Oxidative-Stress-Associated Molecular Signatures in Immune-Mediated Diseases: A Systematic Review Integrating Machine Learning and Systems Biology Approaches.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging and autoimmunity intersect through the progressive decline of resilience pathways that maintain physiological stability. Resilience refers to the integrated capacity of molecular, cellular, and systemic mechanisms to repair damage, adapt to stress, and preserve immune tolerance. With advancing age, resilience deteriorates due to chronic inflammation, cellular senescence, epigenetic drift, and metabolic dysfunction. While a wide spectrum of autoimmune diseases exists, this perspective focuses primarily on those that emerge or progress with advancing age, in which a decline in immune resilience rather than congenital immune defects plays the predominant role. These changes weaken adaptive capacity and promote conditions that allow autoreactive lymphocytes to persist, initiating autoimmune pathology. This perspective frames autoimmunity as a sentinel manifestation of resilience collapse rather than an isolated failure of immune tolerance. The objective of this article is to delineate the shared molecular and systemic mechanisms by which age-associated loss of resilience promotes autoimmune susceptibility, and to highlight how this framework can guide both research priorities and therapeutic innovation. By examining convergent pathways across inflammation, senescence, epigenetics, and metabolism, we emphasize that autoimmune disease arises from integrated failures in the networks that sustain homeostasis. Recognizing these connections enables the development of integrated biomarkers to detect resilience decline and identify individuals at risk before clinical onset. It further supports therapeutic strategies aimed at enhancing repair capacity, maintaining immune tolerance, and restoring adaptive responses. Recasting autoimmunity in this framework provides opportunities for preventive interventions and novel treatments with the potential to extend healthspan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.